PDS Biotechnology Corporation
NASDAQ: PDSB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Frank K. Bedu-Addo
- Employees
- 24
- Headquarters
- Princeton, United States
- IPO year
- 2015
- Market cap
- $48.8M
- Website
- https://www.pdsbiotech.com
Loading PDSB…
Loading profile data…Frequently asked questions about PDSB
What does PDS Biotechnology Corporation (PDSB) do?
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, h...
Where does PDSB trade?
PDS Biotechnology Corporation (PDSB) trades on the NASDAQ Capital Market.
What sector is PDSB in?
PDS Biotechnology Corporation (PDSB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of PDS Biotechnology Corporation?
Frank K. Bedu-Addo is the chief executive officer of PDS Biotechnology Corporation (PDSB).
Where is PDS Biotechnology Corporation headquartered?
PDS Biotechnology Corporation is headquartered in United States.
Does PDSB pay a dividend?
PDS Biotechnology Corporation (PDSB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PDSB go public?
PDS Biotechnology Corporation (PDSB) completed its initial public offering in 2015.